Moderna, Inc. (NASDAQ:MRNA) Shares Sold by Toronto Dominion Bank

Toronto Dominion Bank decreased its position in Moderna, Inc. (NASDAQ:MRNA) by 33.0% during the 1st quarter, Holdings Channel reports. The fund owned 133,777 shares of the company’s stock after selling 65,955 shares during the quarter. Toronto Dominion Bank’s holdings in Moderna were worth $14,255,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds have also made changes to their positions in the company. Cedar Wealth Management LLC increased its position in Moderna by 45.0% during the 1st quarter. Cedar Wealth Management LLC now owns 290 shares of the company’s stock worth $31,000 after purchasing an additional 90 shares during the period. Allworth Financial LP boosted its stake in shares of Moderna by 6.5% in the fourth quarter. Allworth Financial LP now owns 1,660 shares of the company’s stock valued at $165,000 after buying an additional 101 shares in the last quarter. TIAA Trust National Association grew its holdings in Moderna by 2.3% during the fourth quarter. TIAA Trust National Association now owns 4,491 shares of the company’s stock worth $447,000 after acquiring an additional 102 shares during the period. Principle Wealth Partners LLC raised its position in Moderna by 4.3% in the first quarter. Principle Wealth Partners LLC now owns 2,497 shares of the company’s stock worth $266,000 after acquiring an additional 102 shares in the last quarter. Finally, EverSource Wealth Advisors LLC lifted its holdings in Moderna by 32.3% in the fourth quarter. EverSource Wealth Advisors LLC now owns 475 shares of the company’s stock valued at $47,000 after acquiring an additional 116 shares during the period. 75.33% of the stock is currently owned by institutional investors and hedge funds.

Moderna Trading Up 1.4 %

Shares of MRNA stock traded up $1.71 during trading hours on Friday, hitting $122.11. 1,884,844 shares of the company were exchanged, compared to its average volume of 4,016,060. The firm has a fifty day moving average of $134.57 and a 200 day moving average of $115.01. The company has a quick ratio of 3.91, a current ratio of 4.03 and a debt-to-equity ratio of 0.04. Moderna, Inc. has a 1 year low of $62.55 and a 1 year high of $170.47. The firm has a market cap of $46.80 billion, a PE ratio of -7.79 and a beta of 1.66.

Moderna (NASDAQ:MRNA) last posted its quarterly earnings results on Thursday, May 2nd. The company reported ($3.07) earnings per share for the quarter, topping analysts’ consensus estimates of ($3.59) by $0.52. Moderna had a negative net margin of 115.82% and a negative return on equity of 20.10%. The company had revenue of $167.00 million for the quarter, compared to the consensus estimate of $93.26 million. During the same quarter last year, the firm posted $0.19 earnings per share. Moderna’s revenue was down 91.0% on a year-over-year basis. Analysts expect that Moderna, Inc. will post -7.46 earnings per share for the current year.

Insider Activity at Moderna

In other news, Director Noubar Afeyan sold 15,000 shares of Moderna stock in a transaction dated Wednesday, May 1st. The stock was sold at an average price of $110.92, for a total value of $1,663,800.00. Following the transaction, the director now directly owns 2,026,931 shares of the company’s stock, valued at approximately $224,827,186.52. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. In related news, President Stephen Hoge sold 255 shares of the company’s stock in a transaction on Friday, May 10th. The shares were sold at an average price of $120.96, for a total transaction of $30,844.80. Following the completion of the sale, the president now directly owns 1,486,508 shares of the company’s stock, valued at approximately $179,808,007.68. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Noubar Afeyan sold 15,000 shares of the firm’s stock in a transaction dated Wednesday, May 1st. The shares were sold at an average price of $110.92, for a total value of $1,663,800.00. Following the completion of the transaction, the director now directly owns 2,026,931 shares in the company, valued at $224,827,186.52. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 396,239 shares of company stock worth $55,428,337. 15.70% of the stock is owned by insiders.

Analyst Ratings Changes

A number of equities analysts have recently weighed in on MRNA shares. William Blair reaffirmed a “market perform” rating on shares of Moderna in a research note on Thursday, June 27th. Oppenheimer upped their target price on shares of Moderna from $163.00 to $179.00 and gave the stock an “outperform” rating in a research report on Wednesday, June 12th. Jefferies Financial Group reiterated a “buy” rating and set a $125.00 price target on shares of Moderna in a research report on Tuesday, April 9th. Needham & Company LLC restated a “hold” rating on shares of Moderna in a report on Friday, June 28th. Finally, Royal Bank of Canada raised their price objective on Moderna from $135.00 to $160.00 and gave the company an “outperform” rating in a research note on Monday, June 3rd. Two research analysts have rated the stock with a sell rating, nine have assigned a hold rating and seven have given a buy rating to the company’s stock. According to MarketBeat, Moderna presently has an average rating of “Hold” and an average price target of $133.88.

Moderna Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.